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Classic strategies for peripheral blood progenitor cell (PBPC)
mobilization include daily administration of a growth factor, such
as ﬁlgrastim, alone or with marrow suppressive chemotherapy. A
single injection of pegﬁlgrastim has been shown to be comparable
to daily injections of ﬁlgrastim in the treatment of chemotherapy-
induced neutropenia. One of the objectives of this phase 1–2 study
was to provide dose-ﬁnding information regarding the efﬁcacy and
kinetics of cytokine-alone PBPC mobilization with pegﬁlgrastim.
Methods: Chemotherapy-naive subjects with a variety of solid
tumors were randomized to receive a single administration of 6, 12,
or 18 mg of pegﬁlgrastim on day 1 or daily administration of 10
g/kg ﬁlgrastim from day 1 until day 7. Daily blood samples for
peripheral CD34 analysis were collected on days 1–7 and then on
days 9 and 12. No chemotherapy was administered during this
cycle. For each subject, peak CD34 cell count was deﬁned as the
maximum cell count observed between days 3 to 7, inclusive.
Results: Of 61 subjects randomized into the study, all received
study drug (15 subjects each in the pegﬁlgrastim 12 mg and 18 mg
and ﬁlgrastim groups and 16 subjects in the pegﬁlgrastim 6 mg
group). The treatment groups were balanced in terms of demo-
graphics and baseline characteristics. The most common tumor
types were non-small cell lung cancer (n  23 [38%]) and ovarian
(n  19 [31%]). The mean peak CD34 cell count was similar in
the ﬁlgrastim and pegﬁlgrastim 6mg groups (4.51 and 4.24 
104/ml, respectively), whereas the pegﬁlgrastim 12 mg and 18 mg
groups had higher mean peaks (8.18 and 9.96  104/ml, respec-
tively). Pegﬁlgrastim 12 mg and 18 mg mobilized signiﬁcantly
more peripheral CD34 cells than ﬁlgrastim (P  .034 and .006,
respectively). The subject incidence of SAEs was low and compa-
rable between groups. Conclusion: In chemotherapy-naive sub-
jects with solid tumor, single-day administration of pegﬁlgrastim is
at least as efﬁcacious as repeated daily injections of ﬁlgrastim (10
g/kg) in its ability to successfully mobilize peripheral CD34
cells. A dose-response relationship of CD34 mobilization is ob-
served. Pegﬁlgrastim 12 mg and 18 mg mobilize higher numbers of
CD34 cells than does daily administration of ﬁlgrastim. Pegﬁl-
grastim at 6 mg, 12 mg, and 18 mg is generally safe and well
tolerated in this setting. The trial is ongoing, and updated results
on safety and efﬁcacy will be presented.
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SYSTEMIC AL AMYLOIDOSIS (AL)
Cohen, A.D.; Zhou, P.; Reich, L.; Fircanis, S.; Drake, L.; Hedvat, C.;
Teruya-Feldstein, J.; Filippa, D.A.; Fleisher, M.; Comenzo, R.L.
Memorial Sloan-Kettering Cancer Center, New York, NY.
High-dose melphalan (M) with autologous stem cell transplant
(ASCT) is effective therapy for AL, but treatment-related mortal-
ity (TRM) remains high, and hematologic complete responses
(CR) occur in a minority of patients. In this study, we investigated
whether a risk-adapted approach to intravenous (IV) M dosing
could decrease TRM, and whether adjuvant D 	 T could improve
hematologic and amyloid-involved organ response rates. Low-risk
patients (1 or 2 major organs involved, no advanced cardiac disease)
receive M 100, 140, or 200 mg/m2 with ASCT based on age,
cardiac involvement, and renal function. High-risk patients (3
organs involved or advanced cardiac disease) receive 2 cycles of M
40 mg/m2 without ASCT. Patients with persistent clonal plasma
cell disease at 3 months receive 9 months of adjuvant DT or D
alone (if history of deep venous thrombosis or neuropathy). Since
September 2002, 39 patients (median age, 58 years; range, 34–73
years; 67% male) have enrolled for a median of 1.5 months (range,
0.5–7 months) from diagnosis. Organ involvement includes 13
(33%) cardiac, 25 (64%) renal (13 with renal only), 13 (33%)
liver/GI tract, and 10 (26%) peripheral nervous system. Only 4
high-risk patients have enrolled; all had symptomatic cardiac in-
volvement and died a median of 4 months (range, 2.5–6 months)
after M. Thirty-four patients in the low-risk group have been
treated, and TRM is 6.4% (2/31), with an additional 3 patients
alive 100 days posttreatment. Four low-risk patients have died of
progressive disease (PD) a median of 11.7 months (range, 7–18
months) after M. At 3 months, 19/30 (63%) evaluable low-risk
patients had hematologic responses (5 CR, 14 PR) and 11 had
stable disease. Twenty patients with persistent clonal disease began
adjuvant therapy with D 	 T. At 12 months, 11/15 (73%) evalu-
able patients had responses (5 CR, 6 PR) and 8 (67%) had objective
improvement in amyloid-related organ function. Preliminary anal-
ysis of serum free light chain data (n  31) shows an association
between a persistently abnormal 
: ratio 3 months after treatment
and an increased risk of death (relative risk 1.54; 95% conﬁdence
interval  1.12–2.12; P  .02). Analyses of the prognostic signif-
icance of serial troponin and BNP levels and plasma cell cyclin D1
expression are ongoing. In conclusion, risk-adapted dosing of IVM
in newly diagnosed AL patients has a low TRM. Adjuvant D 	 T
is feasible, has moderate toxicity, and has to date beneﬁted 20%
(4/20) of patients with persistent clonal plasma cell disease 3
months post-ASCT.
Adjuvant Therapy* (n  25 Eligible)
Thal/Dex (n) Dex (n)
Began therapy (n  5
refused or too ill) 12 8
Completed 9 mos. 4 3
Still on (<9 mos.) 3 2
Reasons for
discontinuation
PD (n  2),
pulmonary embolus
(1), avascular
necrosis hip (1),
RSV pneumonia (1)
PD (n  2),
intolerance (1)
Benefit to
hematologic
response
SD (@3 mos.)3PR
(@12 mos.) (n 
1), PR3CR (n  1)
SD3PR (n  1),
PR3CR (n 
1)
*Dexamethasone (1 to 3 four-day pulses monthly); Thalidomide
(50–200mg nightly)
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IDENTIFICATION AND TISSUE DISTRIBUTION OF ANTIGEN-SPECIFIC
RECIPIENT ANTI-DONOR CD8 T CELLS THAT RESIST HEMATOPIETIC
ENGRAFTMENT FOLLOWING MHC-MATCHED ALLOGENEIC PROGENI-
TOR CELL TRANSPLANTS
Shatry, A.M.; Levy, R.B. University of Miami Medical School, Miami,
FL.
The role of natural killer (NK) cells in resistance to progenitor
cell (PC) engraftment has been extensively studied in experimental
bone marrow transplantation (BMT). Although antigen-speciﬁc T
cells are believed to be the principal effectors resisting engraftment
following clinical hematopietic cell transplants (HCT), less is
known involving the biology and distribution of these cells follow-
ing experimental HCT. The present studies established a model of
resistance using the well-deﬁned dominant, that is H60 MiHA (in
B6 mice primed to BALB.B; B6BALB.B) to precisely identify and
track host T cells following BMT into recipients sensitized against
donor transplant antigens. We utilized an H60/Kb tetramer and
determined the mean (12.2% 	 0.88 of CD8 cells) frequency of
circulating CD8 H60-speciﬁc T cells (5.6%–20.5%) in B6 re-
cipients before BMT. Most ( 90%) CD8H60 cells expressed
the memory phenotype (CD44, Ly6C, CD25/CD69). Inter-
estingly, the frequency of CD8 H60 T cells was higher in the
bone marrow than in the blood and splenic compartments, sug-
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